<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cycloserine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cycloserine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cycloserine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11708" href="/d/html/11708.html" rel="external">see "Cycloserine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13192" href="/d/html/13192.html" rel="external">see "Cycloserine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F155579"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous;</li>
<li>
                        Antitubercular Agent</li></ul></div>
<div class="block doa drugH1Div" id="F155560"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c2940f0-014f-4362-aba1-d832529ab519">Tuberculosis, drug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug resistant:</b>
<b>Oral:</b> 10 to 15 mg/kg/day (maximum: 1 g/day), usually 250 to 750 mg/day in 1 or 2 divided doses as part of an appropriate combination regimen (ATS/CDC/ERS/IDSA [Nahid 2019]; ATS/CDC/IDSA [Nahid 2016]). <b>Note:</b> Some experts recommend the following 2-week dose titration: 250 mg once daily for 3 to 4 days, 250 mg every 12 hours for 3 to 4 days, then 250 mg in the morning and 500 mg in the evening (Curry International Tuberculosis Center 2016). Adjust based on serum concentration (ATS 2003; ATS/CDC/ERS/IDSA [Nahid 2019]; Curry International Tuberculosis Center 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> Some neurotoxic effects may be treated or prevented by concomitant administration of 200 to 300 mg of pyridoxine daily or 50 mg of pyridoxine per 250 mg of cycloserine (Curry International Tuberculosis Center 2016; WHO 2008).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991397"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use is contraindicated in severe impairment. However, the following adjustments have been used by some clinicians:</p>
<p style="text-indent:-2em;margin-left:2em;">ATS/CDC/IDSA guidelines: CrCl &lt;30 mL/minute or hemodialysis: 250 mg once daily or 500 mg 3 times per week. <b>Note:</b> The appropriateness of 250 mg daily doses has not been established, and careful monitoring is necessary for evidence of neurotoxicity. Monitor serum concentrations to minimize toxicity (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block doha drugH1Div" id="F50988595"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F155561"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; start at lower end of dosage range and use with caution.</p></div>
<div class="block dop drugH1Div" id="F155571"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13192" href="/d/html/13192.html" rel="external">see "Cycloserine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d4ce8b9-c2d8-48d5-9347-306cae012c37">Active tuberculosis infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<b>Active tuberculosis infection (excluding meningitis), treatment (second-line therapy):</b></b> Limited data available: <b>Note</b>: Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations for detailed information. Always use as part of a multidrug regimen (ATS/CDC/IDSA [Nahid 2016]). Concomitant pyridoxine is recommended to prevent cycloserine-induced neuropathy (WHO 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;15 years; weighing ≤40 kg: Oral: 15 to 20 mg/kg/day divided every 12 to 24 hours (if tolerability issues, may divide into 2 doses); maximum daily dose: 1,000 mg/<b>day</b> (ATS/CDC/IDSA 2016; HHS [pediatric 2013]; Seddon 2012). <b>Note:</b> Some patients may be unable to tolerate recommended doses; experts suggest beginning with a low once daily dose and gradually increasing as tolerated; serum concentrations targeted at 25 to 30 mcg/mL have been suggested to minimize toxicity (ATS/CDC/IDSA [Nahid 2016]; HHS [pediatric 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents ≥15 years: Oral: 10 to 15 mg/kg/day divided every 12 to 24 hours; usual dose 250 to 500 mg; maximum daily dose: 1,000 mg/<b>day Note:</b> Patients are often unable to tolerate the maximum dose divided twice daily (eg, in adults, 500 mg twice daily); therefore, experts suggest beginning with a low once daily dose and gradually increasing as tolerated; may consider therapeutic drug monitoring; serum concentrations targeted at 25 to 30 mcg/mL have been suggested to minimize toxicity (ATS/CDC/IDSA [Nahid 2016]; HHS [pediatric 2013]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090774"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use is contraindicated in severe impairment; based on experience in adult patients, dosage adjustment suggested in moderate impairment.</p></div>
<div class="block dohp drugH1Div" id="F51090477"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F155531"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Vitamin B<sub>12</sub> deficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia, behavioral changes, coma, confusion, disorientation, drowsiness, dysarthria, hyperreflexia, paresis, paresthesia, seizure, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Lichenoid eruption (Kim 2017), Stevens-Johnson syndrome (Akula 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Folate deficiency (Klipstein 1967)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Megaloblastic anemia (Klipstein 1967), sideroblastic anemia (Klipstein 1967)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (Kwon 2008), headache (Singanamala 2019), psychiatric disturbance (including aggressive behavior, depression, hallucination, hyperirritability, mania, psychosis, and suicidal tendencies) (Bakhla 2013; Intini 2019; Singanamala 2019)</p></div>
<div class="block coi drugH1Div" id="F155545"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cycloserine or any component of the formulation; epilepsy; depression, severe anxiety, or psychosis; severe renal insufficiency; excessive concurrent use of alcohol</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F155528"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Has been associated with dose-related CNS toxicity, including seizures, psychosis, depression, and confusion; decrease dosage or discontinue use if occurs. Pyridoxine may be coadministered to prevent/treat CNS effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Allergic dermatitis may occur; reduce dose or discontinue use if allergic dermatitis develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcoholism: Use with caution in patients with a history of chronic alcoholism; increased risk of seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mental illness: Use with caution in patients with depression, severe anxiety, and/or psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary. Use is contraindicated in severe renal insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with potential for vitamin deficiency: Use with caution in patients with potential vitamin B<sub>12</sub> and/or folate deficiency (malnourished, chronic antiseizure medication therapy, or elderly).</p></div>
<div class="block foc drugH1Div" id="F155538"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F155524"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F155547"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (cycloSERINE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $91.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F44337695"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer in divided doses with or without food.</p></div>
<div class="block admp drugH1Div" id="F52612468"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to meals; administer with meals to decrease GI distress</p></div>
<div class="block use drugH1Div" id="F155542"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis:</b> Treatment of pulmonary or extrapulmonary tuberculosis (TB) disease (active TB), in combination with other agents, when treatment with primary tuberculosis therapy has proved inadequate</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> May be effective in treatment of acute urinary tract infection caused by susceptible strains of gram-positive and gram-negative bacteria. <b>Note:</b> Should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.</p></div>
<div class="block mst drugH1Div" id="F155586"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CycloSERINE may be confused with cyclobenzaprine, cycloPHOSphamide, cycloSPORINE</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299109"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F155533"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethionamide: May enhance the adverse/toxic effect of CycloSERINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the adverse/toxic effect of CycloSERINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terizidone: May enhance the adverse/toxic effect of CycloSERINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F155555"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">May increase vitamin B<sub>12</sub> and folic acid dietary requirements. Management: Vitamin B<sub>12</sub> and folic acid supplementation may be needed.</p></div>
<div class="block rep_considerations drugH1Div" id="F54904831"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to treatment of multidrug resistant tuberculosis in females of reproductive potential. Females of reproductive potential should use effective contraception during treatment for multidrug-resistant tuberculosis (Esmail 2018).</p></div>
<div class="block pri drugH1Div" id="F13494780"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cycloserine crosses the placenta and can be detected in the fetal blood and amniotic fluid.</p>
<p style="text-indent:0em;margin-top:2em;">Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data are limited for use of second-line drugs in pregnancy (ie, cycloserine). The treatment of multidrug-resistant tuberculosis in pregnant patients should be individualized; evidence to support a specific regimen is not available (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020).</p></div>
<div class="block brc drugH1Div" id="F13494781"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cycloserine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Cycloserine levels in breast milk are similar to those found in the maternal serum. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, considering the importance of treatment to the mother. Patients with multidrug-resistant tuberculosis and a sputum smear-positive test should avoid breastfeeding when possible (Esmail 2018).</p></div>
<div class="block dic drugH1Div" id="F155548"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with food; may increase vitamin B<sub>12</sub> and folic acid dietary requirements.</p></div>
<div class="block mop drugH1Div" id="F155536"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic renal and hematological tests, and plasma cycloserine concentrations; assess neuropsychiatric status at monthly intervals and more frequently if symptoms occur (ATS/CDC/ERS/IDSA [Nahid 2019]; Curry International Tuberculosis Center 2016).</p></div>
<div class="block rer drugH1Div" id="F155539"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic peak (2 hours post-dose) levels: Tuberculosis: 20 to 35 mcg/mL (ATS/CDC/ERS/IDSA [Nahid 2019]; Curry International Tuberculosis Center 2016; ATS 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">Toxicity is greatly increased at levels &gt;35 mcg/mL (Curry International Tuberculosis Center 2016).</p></div>
<div class="block pha drugH1Div" id="F155527"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by competing with amino acid (D-alanine) for incorporation into the bacterial cell wall; bacteriostatic or bactericidal</p></div>
<div class="block phk drugH1Div" id="F155544"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: ~70% to 90% from GI tract (WHO 2008). Absorption is delayed and C<sub>max</sub> lowered when administered with high-fat meal compared to fasting, but AUC not impacted (Zhu 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to most body fluids and tissues including CSF, bile, sputum, lymph tissue, lungs, and ascitic, pleural, and synovial fluids (WHO 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Not plasma protein bound</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 4 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~65% as unchanged drug) within 72 hours; Feces (small amounts); remainder metabolized</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038592"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cyclocat</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Sai lai xing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina antibiotice | Seromycin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cycloserin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Seromycine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina | D Cycloserine</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Seromycin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Seromycin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Coxerin | Cyclorine | Cyclotec | Cyserine | Myser</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cyclomycin | Cycloserine aventis | Cycloserine kyowa | Cycloserine meiji | Cycloserine pfizer | Cycloserine sankyo | Cycloserine sumitomo | Cycloserine takeda | Orientmycin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aspen cycloserine | Coxerin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Closerin | Curos | Cyrine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina antibiotice | Seromycin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cycloserin | Seromycin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Coxerin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina specific</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina | Neoseryn</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cyclocin | Cyclosen | Xerine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina | Coxerin | Cyclorine | Seromycin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Seromycin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cicloserina antibiotice | Helpocerin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Coxerin | Cyclorine | Cycloserin | Cycloserin ferein | Cycloserine ferein | Kansamin | Myser | Myzer</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Seromycin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Seromycin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hawon Cycloserine | Proserine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Seromycin | Siklocap</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cyclocin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Coxerin | Helposerin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Coxerin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9441086">
<a name="9441086"></a>Akula SK, Aruna AS, Johnson JE, Anderson DS. Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis. <i>Int J Tuberc Lung Dis</i>. 1997;1(2):187-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/9441086/pubmed" id="9441086" target="_blank">9441086</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>American Thoracic Society (ATS), CDC, Infectious Diseases Society of America. Treatment of tuberculosis. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24459378">
<a name="24459378"></a>Bakhla AK, Gore PS, Srivastava SL. Cycloserine induced mania. <i>Ind Psychiatry J</i>. 2013;22(1):69-70. doi:10.4103/0972-6748.123636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/24459378/pubmed" id="24459378" target="_blank">24459378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12588714">
<a name="12588714"></a>Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. <i>Am J Respir Crit Care Med</i>. 2003;167(4):603-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/12588714/pubmed" id="12588714" target="_blank">12588714</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Curry International Tuberculosis Center and California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.</div>
</li>
<li>
<div class="reference">
                  Cycloserine capsules [prescribing information]. Princeton, NJ: Dr Reddy’s Laboratories Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379145">
<a name="1379145"></a>Davidson PT, Le HQ. Drug treatment of tuberculosis - 1992. <i>Drugs</i>. 1992;43(5):651-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/1379145/pubmed" id="1379145" target="_blank">1379145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8412982">
<a name="8412982"></a>Drugs for tuberculosis. <i>Med Lett Drugs Ther</i>. 1993;35(908):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/8412982/pubmed" id="8412982" target="_blank">8412982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31806629">
<a name="31806629"></a>Intini E, Kishore G, Richeldi L, Udwadia ZF. Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us. <i>BMJ Case Rep</i>. 2019;12(12):e230993. doi:10.1136/bcr-2019-230993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/31806629/pubmed" id="31806629" target="_blank">31806629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8350889">
<a name="8350889"></a>Iseman MD. Treatment of multidrug-resistant tuberculosis. <i>N Engl J Med</i>. 1993;329(11):784-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/8350889/pubmed" id="8350889" target="_blank">8350889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28293936">
<a name="28293936"></a>Kim J, Park S, Jung CM, Oh CW, Kwon JW. A case of cycloserine-induced lichenoid drug eruption supported by the lymphocyte transformation test. <i>Allergy Asthma Immunol Res</i>. 2017;9(3):281-284. doi:10.4168/aair.2017.9.3.281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/28293936/pubmed" id="28293936" target="_blank">28293936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6023546">
<a name="6023546"></a>Klipstein FA, Berlinger FC, Reed LJ. Folate deficiency associated with drug therapy for tuberculosis. <i>Blood</i>. 1967;29(5):697-712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/6023546/pubmed" id="6023546" target="_blank">6023546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474246">
<a name="24474246"></a>Kugathasan R, Wootton M, Howe R. Cycloserine as an alternative urinary tract infection therapy: susceptibilities of 500 urinary pathogens to standard and alternative therapy antimicrobials. <i>Eur J Clin Microbiol Infect Dis</i>. 2014;33(7):1169-1172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/24474246/pubmed" id="24474246" target="_blank">24474246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18484995">
<a name="18484995"></a>Kwon HM, Kim HK, Cho J, Hong YH, Nam H. Cycloserine-induced encephalopathy: evidence on brain MRI. <i>Eur J Neurol</i>. 2008;15(7):e60-e61. doi:10.1111/j.1468-1331.2008.02171.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/18484995/pubmed" id="18484995" target="_blank">18484995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis.</i> 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4896009">
<a name="4896009"></a>Ormonde NW, Gray JA, Murdoch JM, et al. Chronic bacteriuria due to Escherichia coli. I. Assessment of the value of combined short- and long-term treatment with cycloserine, nitrofurantoin, and sulphadimidine. <i>J Infect Dis</i>. 1969;120(1):82-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/4896009/pubmed" id="4896009" target="_blank">4896009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22983960">
<a name="22983960"></a>Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. <i>Am J Respir Crit Care Med</i>. 2012;186(10):953-964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/22983960/pubmed" id="22983960" target="_blank">22983960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31792104">
<a name="31792104"></a>Singanamala B, Saini L, Madaan P, Singh P, Vaidya PC, Sahu JK. Antitubercular therapy-induced psychosis. <i>Neurology</i>. 2019;93(23):1012-1013. doi:10.1212/WNL.0000000000008578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/31792104/pubmed" id="31792104" target="_blank">31792104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24569199">
<a name="24569199"></a>US Department of Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>Pediatr Infect Dis J</i>. 2013;32(suppl 2)(0 2):i-KK4. doi:10.1097/01.inf.0000437856.09540.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/24569199/pubmed" id="24569199" target="_blank">24569199</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). <i>Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2008 Emergency Update</i>. World Health Organization; 2008</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Management of MDR-TB: a ﬁeld guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). 2009. http://whqlibdoc.who.int/publications/2009/9789241547765_eng.pdf?ua=1. Accessed June 2, 2015.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Rapid advice: treatment of tuberculosis in children. 2010. http://apps.who.int/iris/bitstream/10665/44444/1/9789241500449_eng.pdf. Accessed June 2, 2015.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020. Accessed July 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11718495">
<a name="11718495"></a>Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. <i>Pharmacotherapy</i>. 2001;21(8):891-897. doi:10.1592/phco.21.11.891.34524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cycloserine-drug-information/abstract-text/11718495/pubmed" id="11718495" target="_blank">11718495</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9309 Version 195.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
